The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•7 April 2026•

1 min read

MediWound to Present New EscharEx Clinical Data at Major 2026 Conferences

Key Facts

1MediWound will present new data for EscharEx at three leading wound care conferences in April and May 2026.

2The findings support the ongoing Phase III VALUE study and planned expansion into diabetic foot ulcers and pressure ulcers.

3Presentations include comparisons highlighting EscharEx's advantages over SANTYL.

Version History

2 additional sources confirmed this story

MediWound Ltd. (Nasdaq: MDWD) has announced its plans to present new clinical data for EscharEx at three premier wound care conferences in April and May 2026. The presentations will take place at the Wound Healing Society (WHS), the Symposium on Advanced Wound Care (SAWC), and the European Wound Management Association (EWMA). These findings are expected to support the company's ongoing Phase III VALUE study and its planned expansion into treating diabetic foot and pressure ulcers. Notably, the data will include comparative analyses highlighting the competitive advantages of EscharEx over the existing treatment SANTYL. This move aims to showcase the therapeutic's mechanism of action and clinical outcomes to a global audience of medical professionals. The increased visibility at these major events signals confidence in the product's clinical progress and market potential.